1380 related articles for article (PubMed ID: 22112373)
1. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
2. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
Ben Yakov G; Montano D; Abu Freha N; Etzion O; Dizingof V; Mushkalo A; Shwarts D; Monitin S; Takchick A; Zilberman D; Sikuler E; Fich A
Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553
[TBL] [Abstract][Full Text] [Related]
3. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
Barritt AS; Fried MW
Gastroenterology; 2012 May; 142(6):1314-1323.e1. PubMed ID: 22537438
[TBL] [Abstract][Full Text] [Related]
4. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
Ferenci P; Reddy KR
Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
[TBL] [Abstract][Full Text] [Related]
5. Simeprevir for the treatment of chronic hepatitis C.
You DM; Pockros PJ
Expert Opin Pharmacother; 2013 Dec; 14(18):2581-9. PubMed ID: 24138198
[TBL] [Abstract][Full Text] [Related]
6. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.
Pearlman BL
Lancet Infect Dis; 2012 Sep; 12(9):717-28. PubMed ID: 22647717
[TBL] [Abstract][Full Text] [Related]
7. Seizures in patients with chronic hepatitis C treated with NS3/4A protease inhibitors: does pharmacological interaction play a role?
Milazzo L; Falvella FS; Magni C; Gervasoni C; Peri AM; Cattaneo D; Antinori S; Vidale S
Pharmacology; 2013; 92(5-6):235-7. PubMed ID: 24192929
[TBL] [Abstract][Full Text] [Related]
8. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
Foote BS; Spooner LM; Belliveau PP
Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346
[TBL] [Abstract][Full Text] [Related]
9. Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.
Saadoun D; Resche Rigon M; Thibault V; Longuet M; Pol S; Blanc F; Pialoux G; Karras A; Bazin-Karra D; Cazorla C; Vittecoq D; Musset L; Decaux O; Ziza JM; Lambotte O; Cacoub P
Ann Rheum Dis; 2014 May; 73(5):831-7. PubMed ID: 23606708
[TBL] [Abstract][Full Text] [Related]
10. [Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)].
Crespo G; Lens S
Gastroenterol Hepatol; 2012 May; 35(5):337-43. PubMed ID: 22349607
[TBL] [Abstract][Full Text] [Related]
11. Boceprevir: a protease inhibitor for the treatment of hepatitis C.
Chang MH; Gordon LA; Fung HB
Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763
[TBL] [Abstract][Full Text] [Related]
12. [Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
Macías J; Rivero A
Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():33-6. PubMed ID: 24063901
[TBL] [Abstract][Full Text] [Related]
13. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
Ramachandran P; Fraser A; Agarwal K; Austin A; Brown A; Foster GR; Fox R; Hayes PC; Leen C; Mills PR; Mutimer DJ; Ryder SD; Dillon JF
Aliment Pharmacol Ther; 2012 Mar; 35(6):647-62. PubMed ID: 22296568
[TBL] [Abstract][Full Text] [Related]
14. First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients.
Chachá SGF; Rodrigues JPV; Araújo RC; Pereira LRL; Villanova MG; Souza FF; Santana RC; Martinelli ALC
Rev Soc Bras Med Trop; 2018; 51(2):146-154. PubMed ID: 29768546
[TBL] [Abstract][Full Text] [Related]
15. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
16. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
Jacobson IM; Marcellin P; Zeuzem S; Sulkowski MS; Esteban R; Poordad F; Bruno S; Burroughs MH; Pedicone LD; Boparai N; Deng W; DiNubile MJ; Gottesdiener KM; Brass CA; Albrecht JK; Bronowicki JP
Hepatology; 2012 Aug; 56(2):567-75. PubMed ID: 22619063
[TBL] [Abstract][Full Text] [Related]
17. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
Sitole M; Silva M; Spooner L; Comee MK; Malloy M
Clin Ther; 2013 Feb; 35(2):190-7. PubMed ID: 23369368
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of a protease inhibitor with pegylated interferon and ribavirin in patients with untreated chronic hepatitis C: a meta analysis].
Yuan XL; Li MY; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2012 May; 20(5):357-62. PubMed ID: 22971281
[TBL] [Abstract][Full Text] [Related]
19. [Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Rókusz L; Szalay F; Telegdy L; Tornai I; Werling K; Makara M
Orv Hetil; 2015 Mar; 156(9):343-51. PubMed ID: 25702254
[TBL] [Abstract][Full Text] [Related]
20. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
Pascale A; Serfaty L
J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
